




PHARMACEUTICAL 2022

Immunome Inc.
Rank 185 of 466





PHARMACEUTICAL 2022

Immunome Inc.
Rank 185 of 466

The relative strengths and weaknesses of Immunome Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Immunome Inc. is the variable Net Income, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 94% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	56,638
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,728
Liabilities, Non-Current	0
Other Assets	432
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12
Other Net Income	493
Other Revenues	0
Property and Equipment	855
Research and Development	14,110
Selling, General and Administrative Expense	11,094

Output Variable	Value in 1000 USD
Assets	57,925
Liabilities	9,740
Expenses	25,204
Revenues	0
Stockholders Equity	48,185
Net Income	-24,711
Comprehensive Net Income	-24,711
Economic Capital Ratio	172%